NCT07239453

Brief Summary

This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Oct 2025

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 20, 2025

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

November 16, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 20, 2025

Completed
11 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

November 20, 2025

Status Verified

November 1, 2025

Enrollment Period

1 month

First QC Date

November 16, 2025

Last Update Submit

November 16, 2025

Conditions

Infective Disorder

Outcome Measures

Primary Outcomes (2)

  • AUCt

    pre-dose ~ 72 hr of pose-dose

  • Cmax

    pre-dose ~ 72 hr of post-dose

Study Arms (2)

Sequence A

EXPERIMENTAL
Drug: DA-2902Drug: DA-2902-R

Sequence B

EXPERIMENTAL
Drug: DA-2902Drug: DA-2902-R

Interventions

DA-2902DRUG

single dose administration (DA-2902 one tablet once a day)

Sequence ASequence B
DA-2902-RDRUG

single dose administration (DA-2902-R one tablet once a day)

Sequence ASequence B

Eligibility Criteria

Age19 Years - 44 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy volunteers
  • BMI between 18 and 30 kg/m2
  • Body weight: Male≥50kg, Female≥45kg
  • Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study

You may not qualify if:

  • Subjects with clinically significant medical history
  • Subjects with history of drug abuse or addicted
  • Subjects with allergy or drug hypersensitivity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHA University Bundang Medical Center

Seongnam-si, Gyeonggi-do, 13520, South Korea

Location

MeSH Terms

Conditions

Communicable Diseases

Condition Hierarchy (Ancestors)

InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 16, 2025

First Posted

November 20, 2025

Study Start

October 20, 2025

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

November 20, 2025

Record last verified: 2025-11

Locations

KR(1)